- Home
- RLYB
RLYB
Rallybio Corporation
as 03-27-2025 4:00pm EST
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 27.2M | IPO Year: | 2021 |
| Target Price: | $9.75 | AVG Volume (30 days): | 43.8K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.61 - $3.46 | Next Earning Date: | 03-13-2025 |
| Revenue: | $636,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -59.91% | Revenue Growth (next year): | N/A |
Latest Rallybio Corporation News
RLYB Breaking Stock News: Dive into RLYB Ticker-Specific Updates for Smart Investing
Business Wire
15 days ago
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Simply Wall St.
24 days ago
Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?
Business Wire
a month ago
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference
Clinical Trials Arena
a month ago
Rallybio doses first subject in Phase II trial of treatment for FNAIT in Europe
Business Wire
a month ago
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
Business Wire
3 months ago
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
Simply Wall St.
4 months ago
US Penny Stocks To Consider In December 2024
Business Wire
4 months ago
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
Compare RLYB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLYB Rallybio Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.